NasdaqGS:AUTLBiotechs
Can Autolus Therapeutics' (AUTL) Expanding Obe-cel Reach Bolster Its Position in Cell Therapy?
Autolus Therapeutics recently reported its third quarter results, showing a reduction in net loss to US$79.12 million versus US$82.09 million a year ago, and announced operational advances including broad US market access for Obe-cel with 60 authorized treatment centers and a manufacturing success rate above 90%.
The company is also progressing with clinical programs in pediatric ALL, lupus nephritis, and progressive multiple sclerosis, and announced leadership changes as it prepares for key...